After a baseball collision, a 51-year-old man presents with bradycardia that progresses to shock; imaging finds a large ...

THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing ...

Intraperitoneal chemotherapy is a treatment for cancers in the abdomen or belly area. This treatment delivers anti-cancer drugs directly into the peritoneal cavity, the area in the belly that contains ...

Intraperitoneal (IP) chemotherapy is a type of ovarian cancer treatment in which chemo drugs are directly pumped into your belly cavity (also called peritoneal cavity). When you get chemo this way, it ...

Standard chemotherapy for newly diagnosed ovarian cancer is a platinum–taxane combination. The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel ...

In patients with tumors confined to the peritoneal cavity, there is established pharmacokinetic and tumor biology-related evidence that intraperitoneal drug administration is advantageous. Three large ...

Adding intraperitoneal paclitaxel to intravenous paclitaxel plus oral S-1 improved overall survival in patients with gastric cancer and peritoneal metastasis, extending median survival to 19.4 months ...

HIPEC surgery is a promising treatment option for patients with certain abdominal cancers. Surgical oncologist Erin Ward, MD, discusses which patients would be best candidates for HIPEC, explains why ...

In clinical practice, only a few risk factors remain that can be modified based on the decisions of patients and their physicians. The surgical decision making and chemotherapy administration choices, ...

WEST PHILADELPHIA (WPVI) -- Chemotherapy is a lifesaver in cancer treatment. But an IV isn't always the best way to deliver it. A different technique is helping make a difference for some abdominal ...

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer The study included 523 patients from 23 centers in four French ...